Tango Therapeutics, Inc. - Director's Dealing 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Tango Therapeutics, Inc. (TNGX)
CIK: 0001819133
Period of Report: 2021-08-10

Reporting Person: Weber Barbara (Director, Chief Executive Officer)

Security	Shares	Ownership
Common Stock	1367592	Direct

Security	Exercise Price	Expiration	Underlying	Ownership
Stock Option (Right to Buy)	$1.531	2029-01-24	Common Stock (219164)	Direct
Stock Option (Right to Buy)	$1.648	2030-01-30	Common Stock (219164)	Direct
Stock Option (Right to Buy)	$3.503	2031-01-27	Common Stock (1284137)	Direct

F1: This option shall vest and become exercisable in equally monthly installments over a period of 48 months from January 1, 2019.

F2: This option shall vest and become exercisable in monthly installments over a period of 48 months from January 1, 2020.

F3: This option shall vest and become exercisable in monthly installments over a period of 48 months from January 1, 2021.